Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

PDUFA VI “Breakthrough” Fee Unlikely; FDA Wants Fewer Obligations, Not New Metrics

This article was originally published in RPM Report

Executive Summary

FDA Office of New Drugs Director John Jenkins is making a case against adding “Breakthrough” user fees to PDUFA VI to better fund the program and cut back on the number of unqualified requests for designation. Rather than seek additional funding for specific programs, FDA wants fewer obligations under the user fee program; the agency is pushing back against industry proposals to add more formal meetings.


Related Content

PDUFA VI: Innovative Trial Design Talks Can’t Have Formal Meeting Goals, FDA Says
FDA’s “Breakthrough” Exceeds Expectations; Will It Break The Bank?